NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/26/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization10.86 mln
Float8.76 mln
Earnings Date08/12/2026
Piotroski F-Score
3
/ 9
Below average
Relative Strength
5
/ 100
Severely lagging
Debt / Equity
0.59
Moderate leverage
ROE
-4,317
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
BioCardia is a Sunnyvale, California-based medical company focused on developing treatments that use living cells to repair damage caused by heart and lung disease. Its most advanced treatment, CardiAMP, uses a patient's own cells to address severe heart failure and is currently in a Phase III clinical trial. The company also has several other therapies in earlier stages of testing, including treatments using donor stem cells for heart failure and respiratory conditions. Alongside its therapies, BioCardia offers specialized tools that help doctors deliver treatments precisely and safely to the heart.
